Symbols / MXCT Stock $0.88 +7.63% MaxCyte, Inc.

Healthcare • Medical Devices • United States • NMS
MXCT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Maher Masoud
Exch · Country NMS · United States
Market Cap 94.04M
Enterprise Value 2.27M
Income -44.63M
Sales 33.03M
FCF (ttm) -15.47M
Book/sh 1.61
Cash/sh 0.96
Employees 91
Insider 10d —
IPO Jul 30, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.29
PEG —
P/S 2.85
P/B 0.55
P/C —
EV/EBITDA -0.06
EV/Sales 0.07
Quick Ratio 7.47
Current Ratio 8.30
Debt/Eq 10.46
LT Debt/Eq —
EPS (ttm) -0.42
EPS next Y -0.27
EPS Growth —
Revenue Growth -16.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2026-03-24
ROA -12.60%
ROE -23.63%
ROIC —
Gross Margin 81.16%
Oper. Margin -94.81%
Profit Margin -135.14%
Shs Outstand 106.86M
Shs Float 97.51M
Insider Own 1.40%
Instit Own 65.81%
Short Float 5.10%
Short Ratio 5.84
Short Interest 5.41M
52W High 2.88
vs 52W High -69.39%
52W Low 0.64
vs 52W Low 36.86%
Beta 1.45
Impl. Vol. 5.47%
Rel Volume 0.63
Avg Volume 1.09M
Volume 684.07K
Target (mean) $4.11
Tgt Median $4.50
Tgt Low $2.43
Tgt High $5.00
# Analysts 4
Recom Buy
Prev Close $0.82
Price $0.88
Change 7.63%
About

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.11
Mean price target
2. Current target
$0.88
Latest analyst target
3. DCF / Fair value
$-2.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.88
Low
$2.43
High
$5.00
Mean
$4.11

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-25 main Craig-Hallum Buy → Buy $5
2025-08-11 down BTIG Buy → Neutral —
2025-08-07 down William Blair Outperform → Market Perform —
2025-03-12 main Stifel Buy → Buy $9
2024-04-23 reit Stephens & Co. Overweight → Overweight $11
2024-03-13 reit Stephens & Co. Overweight → Overweight $11
2024-03-13 main BTIG Buy → Buy $8
2023-11-29 init Craig-Hallum — → Buy $7
2023-10-05 reit Stephens & Co. Overweight → Overweight $12
2023-03-28 reit Stephens & Co. — → Overweight $12
2022-08-15 main BTIG — → Buy $11
2021-08-24 init Stephens & Co. — → Overweight $19
2021-08-24 init William Blair — → Outperform —
2021-08-24 init Cowen & Co. — → Outperform —
2021-08-24 init Stifel — → Buy $18
2021-08-24 init BTIG — → Buy $22
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-27 MASOUD MAHER Chief Executive Officer — 300,000 $0.00 $0
2026-03-17 SWIRSKY DOUGLAS J Chief Financial Officer — 10,142 $0.82 $8,266
2025-08-13 DOUGLAS RICHARD H Director — 80,000 $1.39 $111,040
2025-08-13 ERCK STANLEY C Director — 100,000 $1.37 $137,220
2025-08-13 SWIRSKY DOUGLAS J Chief Financial Officer — 50,000 $1.29 $64,500
2025-08-13 BROOKE WILLIAM W. Director — 50,000 $1.29 $64,500
2025-08-13 MASOUD MAHER Chief Executive Officer — 75,000 $1.37 $102,915
2025-06-25 HEMRAJANI REKHA Director — 10,684 $2.09 $22,378
2025-06-18 DOUGLAS RICHARD H Director — 29,210 $0.00 $0
2025-06-18 ERCK STANLEY C Director — 29,210 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
33.03
-14.50%
38.63
-6.44%
41.29
-6.72%
44.26
Operating Revenue
31.06
-17.18%
37.50
-7.16%
40.39
-6.60%
43.24
Cost Of Revenue
6.22
-12.37%
7.10
+49.73%
4.74
-6.98%
5.10
Reconciled Cost Of Revenue
5.31
-17.77%
6.45
+55.08%
4.16
-15.56%
4.93
Gross Profit
26.80
-14.98%
31.53
-13.73%
36.55
-6.68%
39.16
Operating Expense
72.09
-12.86%
82.72
-2.50%
84.84
+27.54%
66.52
Research And Development
20.82
-6.32%
22.23
-6.68%
23.82
+22.05%
19.51
Selling General And Administration
47.04
-16.53%
56.35
-1.21%
57.04
+28.24%
44.48
Selling And Marketing Expense
18.92
-29.02%
26.66
-1.16%
26.98
+44.61%
18.65
General And Administrative Expense
28.12
-5.31%
29.69
-1.25%
30.07
+16.41%
25.83
Other Gand A
28.12
-5.31%
29.69
-1.25%
30.07
+16.41%
25.83
Total Expenses
78.31
-12.82%
89.82
+0.26%
89.59
+25.08%
71.62
Operating Income
-45.28
+11.55%
-51.20
-6.00%
-48.30
-76.52%
-27.36
Total Operating Income As Reported
-51.90
-1.37%
-51.20
-6.00%
-48.30
-76.52%
-27.36
EBITDA
-40.14
+13.50%
-46.41
-6.11%
-43.73
-77.32%
-24.66
Normalized EBITDA
-33.53
+27.75%
-46.41
-6.11%
-43.73
-77.32%
-24.66
Reconciled Depreciation
5.14
+7.35%
4.79
+4.91%
4.57
+69.24%
2.70
EBIT
-45.28
+11.55%
-51.20
-6.00%
-48.30
-76.52%
-27.36
Total Unusual Items
-6.61
0.00
—
—
Total Unusual Items Excluding Goodwill
-6.61
0.00
—
—
Special Income Charges
-6.61
0.00
—
—
Impairment Of Capital Assets
3.55
0.00
—
—
Restructuring And Mergern Acquisition
3.06
0.00
—
—
Net Income
-44.63
-8.71%
-41.05
-8.26%
-37.92
-60.89%
-23.57
Pretax Income
-44.63
-8.71%
-41.05
-8.26%
-37.92
-60.89%
-23.57
Net Non Operating Interest Income Expense
7.27
-28.35%
10.14
-2.26%
10.38
+164.90%
3.92
Interest Expense Non Operating
—
—
—
0.13
Net Interest Income
7.27
-28.35%
10.14
-2.26%
10.38
+164.90%
3.92
Interest Expense
—
—
—
0.13
Interest Income Non Operating
7.27
-28.35%
10.14
-2.26%
10.38
+164.90%
3.92
Interest Income
7.27
-28.35%
10.14
-2.26%
10.38
+164.90%
3.92
Other Income Expense
-6.61
—
—
-0.13
Other Non Operating Income Expenses
—
—
—
-0.13
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-44.63
-8.71%
-41.05
-8.26%
-37.92
-60.89%
-23.57
Net Income From Continuing Operation Net Minority Interest
-44.63
-8.71%
-41.05
-8.26%
-37.92
-60.89%
-23.57
Net Income From Continuing And Discontinued Operation
-44.63
-8.71%
-41.05
-8.26%
-37.92
-60.89%
-23.57
Net Income Continuous Operations
-44.63
-8.71%
-41.05
-8.26%
-37.92
-60.89%
-23.57
Normalized Income
-38.02
+7.40%
-41.05
-8.26%
-37.92
-60.89%
-23.57
Net Income Common Stockholders
-44.63
-8.71%
-41.05
-8.26%
-37.92
-60.89%
-23.57
Diluted EPS
-0.42
-7.69%
-0.39
-5.41%
-0.37
-60.87%
-0.23
Basic EPS
-0.42
-7.69%
-0.39
-5.41%
-0.37
-60.87%
-0.23
Basic Average Shares
106.43
+1.51%
104.85
+1.53%
103.27
+1.54%
101.70
Diluted Average Shares
106.43
+1.51%
104.85
+1.53%
103.27
+1.54%
101.70
Diluted NI Availto Com Stockholders
-44.63
-8.71%
-41.05
-8.26%
-37.92
-60.89%
-23.57
Depreciation Amortization Depletion Income Statement
4.23
+2.00%
4.14
+3.96%
3.98
+57.63%
2.53
Depreciation And Amortization In Income Statement
4.23
+2.00%
4.14
+3.96%
3.98
+57.63%
2.53
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
202.51
-15.44%
239.47
-10.74%
268.27
-6.41%
286.65
Current Assets
118.37
-31.05%
171.68
-9.73%
190.19
-24.61%
252.27
Cash Cash Equivalents And Short Term Investments
103.04
-33.30%
154.48
-8.20%
168.29
-25.98%
227.34
Cash And Cash Equivalents
20.07
-28.04%
27.88
-40.04%
46.51
+320.30%
11.06
Other Short Term Investments
82.98
-34.45%
126.60
+3.95%
121.78
-43.69%
216.28
Receivables
3.50
-25.18%
4.68
-18.97%
5.78
-55.85%
13.09
Accounts Receivable
3.50
-25.18%
4.68
-18.97%
5.78
-55.85%
13.09
Inventory
7.55
-15.34%
8.91
-27.11%
12.23
+42.51%
8.58
Raw Materials
3.86
-18.08%
4.72
-17.16%
5.69
+0.76%
5.65
Work In Process
0.50
+85.56%
0.27
-51.61%
0.56
0.00
Finished Goods
3.18
-18.97%
3.93
-34.30%
5.98
+103.99%
2.93
Prepaid Assets
—
—
—
—
Other Current Assets
4.28
+18.55%
3.61
-7.51%
3.90
+19.67%
3.26
Total Non Current Assets
84.14
+24.12%
67.79
-13.18%
78.08
+127.06%
34.39
Net PPE
28.45
-6.64%
30.47
-12.32%
34.75
+3.50%
33.58
Gross PPE
45.72
+3.74%
44.06
-2.16%
45.04
+13.02%
39.85
Accumulated Depreciation
-17.26
-27.02%
-13.59
-32.14%
-10.29
-63.92%
-6.28
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
17.18
+5.41%
16.30
-0.60%
16.39
+28.71%
12.74
Construction In Progress
0.91
+233.82%
0.27
-12.26%
0.31
-50.56%
0.63
Other Properties
12.84
+0.56%
12.77
-6.66%
13.68
+11.30%
12.29
Leases
14.79
+0.41%
14.73
+0.50%
14.65
+3.23%
14.20
Goodwill And Other Intangible Assets
0.65
0.00
—
—
Other Intangible Assets
0.65
—
—
—
Investments And Advances
52.57
+46.92%
35.78
-16.67%
42.94
0.00
Other Non Current Assets
2.47
+61.03%
1.53
+294.85%
0.39
-52.04%
0.81
Total Liabilities Net Minority Interest
31.02
-6.63%
33.22
-8.00%
36.11
+10.47%
32.69
Current Liabilities
14.27
-9.56%
15.78
-11.65%
17.86
+15.74%
15.43
Payables And Accrued Expenses
9.21
-4.63%
9.66
-19.58%
12.01
+40.38%
8.56
Payables
1.40
+3.17%
1.36
+82.77%
0.74
+154.45%
0.29
Accounts Payable
1.40
+3.17%
1.36
+82.77%
0.74
+154.45%
0.29
Current Accrued Expenses
7.81
-5.90%
8.30
-26.33%
11.27
+36.35%
8.27
Current Debt And Capital Lease Obligation
1.46
+68.52%
0.86
+11.63%
0.77
+392.99%
0.16
Current Capital Lease Obligation
1.46
+68.52%
0.86
+11.63%
0.77
+392.99%
0.16
Current Deferred Liabilities
3.60
-31.48%
5.25
+3.59%
5.07
-24.49%
6.71
Current Deferred Revenue
3.60
-31.48%
5.25
+3.59%
5.07
-24.49%
6.71
Total Non Current Liabilities Net Minority Interest
16.75
-3.98%
17.44
-4.43%
18.25
+5.76%
17.26
Long Term Debt And Capital Lease Obligation
16.49
-3.98%
17.17
-4.45%
17.97
+12.74%
15.94
Long Term Capital Lease Obligation
16.49
-3.98%
17.17
-4.45%
17.97
+12.74%
15.94
Other Non Current Liabilities
0.26
-4.01%
0.27
-3.18%
0.28
-78.56%
1.32
Stockholders Equity
171.49
-16.85%
206.25
-11.16%
232.17
-8.58%
253.97
Common Stock Equity
171.49
-16.85%
206.25
-11.16%
232.17
-8.58%
253.97
Capital Stock
1.07
+1.04%
1.06
+1.63%
1.04
+1.56%
1.02
Common Stock
1.07
+1.04%
1.06
+1.63%
1.04
+1.56%
1.02
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
106.79
+1.02%
105.71
+1.68%
103.96
+1.53%
102.40
Ordinary Shares Number
106.79
+1.02%
105.71
+1.68%
103.96
+1.53%
102.40
Additional Paid In Capital
431.90
+2.34%
422.05
+3.72%
406.93
+4.12%
390.82
Retained Earnings
-261.48
-20.58%
-216.85
-23.35%
-175.80
-27.51%
-137.88
Total Equity Gross Minority Interest
171.49
-16.85%
206.25
-11.16%
232.17
-8.58%
253.97
Total Capitalization
171.49
-16.85%
206.25
-11.16%
232.17
-8.58%
253.97
Working Capital
104.10
-33.23%
155.91
-9.53%
172.34
-27.23%
236.84
Invested Capital
171.49
-16.85%
206.25
-11.16%
232.17
-8.58%
253.97
Total Debt
17.94
-0.50%
18.03
-3.78%
18.74
+16.45%
16.09
Capital Lease Obligations
17.94
-0.50%
18.03
-3.78%
18.74
+16.45%
16.09
Net Tangible Assets
170.84
-17.17%
206.25
-11.16%
232.17
-8.58%
253.97
Tangible Book Value
170.84
-17.17%
206.25
-11.16%
232.17
-8.58%
253.97
Available For Sale Securities
52.57
+46.92%
35.78
-16.67%
42.94
—
Investmentin Financial Assets
52.57
+46.92%
35.78
-16.67%
42.94
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-34.41
-24.63%
-27.61
-27.32%
-21.69
-46.70%
-14.78
Cash Flow From Continuing Operating Activities
-34.41
-24.63%
-27.61
-27.32%
-21.69
-46.70%
-14.78
Net Income From Continuing Operations
-44.63
-8.71%
-41.05
-8.26%
-37.92
-60.89%
-23.57
Depreciation Amortization Depletion
5.14
+7.35%
4.79
+4.91%
4.57
+69.24%
2.70
Depreciation
5.14
+7.35%
4.79
+4.91%
4.57
+69.24%
2.70
Depreciation And Amortization
5.14
+7.35%
4.79
+4.91%
4.57
+69.24%
2.70
Other Non Cash Items
0.08
+31.75%
0.06
-32.98%
0.09
-88.85%
0.84
Stock Based Compensation
9.21
-29.58%
13.08
-6.41%
13.98
+18.95%
11.75
Provisionand Write Offof Assets
0.68
-61.83%
1.77
+154.09%
0.70
0.00
Asset Impairment Charge
3.59
+2860.77%
-0.13
-176.02%
0.17
0.00
Operating Gains Losses
0.29
-66.67%
0.86
+2770.00%
0.03
-78.42%
0.14
Gain Loss On Investment Securities
—
—
—
—
Gain Loss On Sale Of PPE
0.29
-66.67%
0.86
+2770.00%
0.03
-78.42%
0.14
Change In Working Capital
-6.12
-715.45%
-0.75
-119.66%
3.82
+196.05%
-3.98
Change In Receivables
1.15
-6.36%
1.23
-82.82%
7.14
+210.14%
-6.48
Changes In Account Receivables
1.15
-6.36%
1.23
-82.82%
7.14
+210.14%
-6.48
Change In Inventory
0.57
-57.78%
1.36
+130.04%
-4.53
-29.80%
-3.49
Change In Prepaid Assets
-0.53
-281.23%
0.29
+145.71%
-0.64
-300.31%
0.32
Change In Payables And Accrued Expense
-3.72
-97.61%
-1.88
-157.90%
3.25
+2268.00%
-0.15
Change In Payable
-3.72
-97.61%
-1.88
-157.90%
3.25
+2268.00%
-0.15
Change In Account Payable
-3.72
-97.61%
-1.88
-157.90%
3.25
+2268.00%
-0.15
Change In Other Working Capital
-1.68
-1021.98%
0.18
+111.07%
-1.64
-4735.29%
-0.03
Change In Other Current Assets
-0.72
+40.31%
-1.21
-388.12%
0.42
+185.57%
-0.49
Change In Other Current Liabilities
-1.19
-66.16%
-0.72
-317.44%
-0.17
-102.71%
6.35
Investing Cash Flow
25.93
+274.13%
6.93
-87.39%
54.98
+321.50%
-24.82
Cash Flow From Continuing Investing Activities
25.93
+274.13%
6.93
-87.39%
54.98
+321.50%
-24.82
Net PPE Purchase And Sale
-1.77
-7.09%
-1.65
+55.27%
-3.69
+80.02%
-18.48
Purchase Of PPE
-1.77
-7.09%
-1.65
+55.38%
-3.70
+79.98%
-18.48
Sale Of PPE
—
0.00
-100.00%
0.01
0.00
Capital Expenditure
-1.77
-7.09%
-1.65
+55.38%
-3.70
+79.98%
-18.48
Net Investment Purchase And Sale
29.48
+243.42%
8.58
-85.37%
58.67
+1024.60%
-6.35
Purchase Of Investment
-126.29
+16.29%
-150.86
+40.86%
-255.09
+12.32%
-290.94
Sale Of Investment
155.76
-2.31%
159.44
-49.19%
313.77
+10.25%
284.60
Net Business Purchase And Sale
-1.77
0.00
—
—
Purchase Of Business
-1.77
0.00
—
—
Financing Cash Flow
0.66
-68.09%
2.06
-4.06%
2.14
-25.80%
2.89
Cash Flow From Continuing Financing Activities
0.66
-68.09%
2.06
-4.06%
2.14
-25.80%
2.89
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
—
—
0.27
0.00
Proceeds From Stock Option Exercised
0.66
-68.09%
2.06
-4.06%
2.14
-25.80%
2.89
Changes In Cash
-7.82
+58.01%
-18.62
-152.54%
35.44
+196.52%
-36.72
Beginning Cash Position
27.88
-40.04%
46.51
+320.30%
11.06
-76.84%
47.78
End Cash Position
20.07
-28.04%
27.88
-40.04%
46.51
+320.30%
11.06
Free Cash Flow
-36.18
-23.64%
-29.26
-15.26%
-25.39
+23.67%
-33.26
Interest Paid Supplemental Data
—
—
—
0.00
Amortization Of Securities
-2.65
+57.61%
-6.24
+12.33%
-7.12
-166.97%
-2.67
Common Stock Issuance
—
—
0.27
0.00
Issuance Of Capital Stock
—
—
0.27
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category